ADOCIA

📊 Adocia announces its Second Quarter 2026 financial results and provides a business update. 👉 Read more in the complete press release: https://lnkd.in/enZ5Wcm7

🏃♀️🏃♂️ Fiers d'avoir participé à la Boucle du Diabète 2026 ! Cette année, 𝟮𝟯 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲𝘂𝗿𝘀 d'Adocia se sont engagés dans la Boucle du Diabète, parcourant ensemble 𝟭 𝟴𝟯𝟬 𝗸𝗺 au profit de la recherche pour le diabète. 👏 Un grand merci à tous nos collaborateurs pour leur énergie et leur mobilisation, ainsi qu'à Delphine ARDUINI et toute l'équipe de TYPE 1 RUNNING TEAM pour cette belle initiative. #BoucleDuDiabète #Diabète #Engagement #Santé #Innovation #TeamAdocia

ADOCIA invites you to join a virtual KOL event tomorrow to review the full Phase 3 results of BioChaperone® Lispro in people with Type 2 Diabetes in China, providing a comprehensive analysis following the positive topline results reported in July 2025. We are delighted to welcome Dr. Tim Heise (Profil, Neuss, Germany), who will join Adocia's leadership team, Olivier Soula, CEO, and You-Ping Chan, Head of R&D, for an in-depth discussion on the clinical data and future potential of our ultra-rapid insulin candidate. 📅 Tuesday, June 16 ⏰ 10:00 am ET / 4:00 pm CET During this event, we will cover: 🔹 Introduction to BioChaperone® technology platform 🔹 Current mealtime insulin treatment paradigm for Diabetes and limitations 🔹 Ultra-Rapid insulin BC Lispro Phase 3 data on Type 2 Diabetes  🔹 Next steps and potential value creation 🔹 Live Q&A session We look forward to sharing these important results with you. Register here: https://lnkd.in/eYrNMpiV

📊 𝗙𝘂𝗹𝗹 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗕𝗶𝗼𝗖𝗵𝗮𝗽𝗲𝗿𝗼𝗻𝗲® 𝗟𝗶𝘀𝗽𝗿𝗼 in people with type 2 diabetes in China were presented at the 86th American Diabetes Association Scientific Sessions, detailing the positive topline results previously announced in July 2025. The data highlight the potential of BioChaperone® Lispro to 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗴𝗹𝘆𝗰𝗲𝗺𝗶𝗰 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗼𝘂𝘁 𝘁𝗵𝗲 𝗱𝗮𝘆 𝗮𝗻𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝗮𝗹𝗹 𝘁𝗵𝗿𝗲𝗲 𝗱𝗮𝗶𝗹𝘆 𝗺𝗲𝗮𝗹𝘀  compared with Humalog®, one of the world's most widely used mealtime insulins. 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗼𝗻 𝗝𝘂𝗻𝗲 𝟭𝟲, 𝟮𝟬𝟮𝟲, 𝗳𝗼𝗿 𝗮 𝘃𝗶𝗿𝘁𝘂𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 where a leading Key Opinion Leader, Tim Heise (Profil, Neuss, Germany), will provide additional insights into the study results. #ADA2026 #Diabetes #Type2Diabetes #ClinicalResearch #InsulinTherapy #BioChaperone #Innovation #Biotech

Looking forward to today's discussions at the 2nd Annual Obesity & Cardiometabolic Innovation Forum, #SACHS_OCIF. Our CEO & Co-Founder, Olivier Soula, will participate in the panel "Platform Technologies: Obesity Management, Going Beyond BMI", joining fellow industry leaders to discuss innovations shaping the future of obesity and metabolic disease treatments. We are pleased to contribute to these strategic conversations and to exchange perspectives on advancing care for people living with obesity and cardiometabolic disorders. #SACHSOCIF #Biotech #MetabolicDiseases #Obesity #CardiometabolicHealth

📢 𝗔𝗱𝗼𝗰𝗶𝗮 𝗮𝘁 𝗔𝗗𝗔 𝟮𝟬𝟮𝟲 We are pleased to announce that three Adocia programs will be featured at the Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–9, 2026, in Chicago. 🔹 𝗕𝗶𝗼𝗖𝗵𝗮𝗽𝗲𝗿𝗼𝗻𝗲® 𝗟𝗶𝘀𝗽𝗿𝗼 has been selected for both a 𝗽𝗼𝘀𝘁𝗲𝗿 and an 𝗲𝗣𝗼𝘀𝘁𝗲𝗿 𝗧𝗵𝗲𝗮𝘁𝗲𝗿 𝗼𝗿𝗮𝗹 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 highlighting the positive phase 3 clinical trial results. Title: THDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial and Daily Glucose Control vs. Lispro (LIS) in Chinese Patients with Type 2 Diabetes (T2D) 📍 ePoster Theater Presentation - Session Clinical Therapeutics 🗓 Monday, June 8, 2026 | 12:30–1:30 PM CDT  📌 ePoster Theater B (Halls B1-C) 🔹 𝗔𝗱𝗼𝗦𝗵𝗲𝗹𝗹® has been selected for a 𝗽𝗼𝘀𝘁𝗲𝗿 featuring the latest preclinical results supporting the development of our encapsulation technology for pancreatic islet transplantation. Title: Development toward Clinical Application of Adoshell, an Encapsulation System for Pancreatic Islet Transplantation 📍 Poster #2426-P 🗓 Saturday, June 6, 2026 | 12:30–1:30 PM CDT 📌 Poster Hall (Halls D-E) 🔹 𝗔𝗱𝗼𝗫𝗟𝗼𝗻𝗴 has been selected for a 𝗽𝗼𝘀𝘁𝗲𝗿 featuring the first preclinical results demonstrating the potential of our proprietary platform for once-monthly administration of semaglutide. Title : AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations 📍 Poster #3104-LB 🗓 Sunday, June 7, 2026 | 12:30–1:30 PM CDT  📌 Poster Hall (Halls D-E) We look forward to sharing these new data with the diabetes scientific community. #ADA2026 #Adocia #Diabetes #Biotechnology #Innovation #DrugDelivery 

🎥 [Interview] À quelques jours de l’Assemblée Générale d’Adocia, qui se tiendra le mercredi 3 juin, Olivier Soula, Directeur Général, et Stephane Boissel, Président du Conseil d’Administration, se sont exprimés dans LA BOURSE ET LA VIE TV sur les enjeux et perspectives de la société. Au programme de cet échange : ✅ Les récents changements de gouvernance ✅ Les ambitions long terme d’Adocia ✅ Les priorités opérationnelles et scientifiques pour les prochains mois ✅ L’importance de la participation des actionnaires au vote de l’Assemblée Générale ➡️ L’interview complète à découvrir ici : https://lnkd.in/dJWwVazA

📢 Assemblée Générale 2026 d’Adocia — les votes en ligne sont ouverts Les votes en ligne sont désormais ouverts et resteront accessibles jusqu’au 2 juin 2026 à 15h. Nous invitons l’ensemble de nos actionnaires à participer activement en exprimant leur vote dès maintenant. 🕒 Le vote en ligne ne prend que quelques minutes ! 👉 Retrouvez tous les documents relatifs à l’Assemblée Générale ici:  https://lnkd.in/ds5RDJNZ #Adocia #AssembléeGénérale #Gouvernance #Actionnaires #Biotech  

🚀 Charles Fortier, Expert Scientist in Drug Product Development, and David Rigal, Pharmaceutical Operations Director, are heading to Berlin for the 𝗚𝗹𝗼𝗯𝗮𝗹 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 & 𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲, taking place May 18–20, 2026 — and we look forward to connecting with you there! Join Charles Fortier as he presents new results that further expand the scope of application of our 𝗕𝗶𝗼𝗖𝗵𝗮𝗽𝗲𝗿𝗼𝗻𝗲® 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, an innovative technology designed to 𝗼𝘃𝗲𝗿𝗰𝗼𝗺𝗲 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 in peptide and protein co-formulations, including recent advances enabling 𝗵𝗶𝗴𝗵-𝗰𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀. 🔹 𝗧𝗵𝗲 𝗕𝗶𝗼𝗖𝗵𝗮𝗽𝗲𝗿𝗼𝗻𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: 𝗔 𝗧𝗼𝗼𝗹𝗯𝗼𝘅 𝗳𝗼𝗿 𝗦𝗼𝗹𝘃𝗶𝗻𝗴 𝗦𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗜𝘀𝘀𝘂𝗲𝘀 𝗶𝗻 𝗖𝗼-𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀 𝗮𝗻𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻𝘀 📅 Tuesday, May 19, 2026 🕒 12:50 PM – 1:20 PM 📍 Room 4 👉 Learn more about the DDF Summit (Drug Delivery & Formulation) here: https://lnkd.in/etCYsmiW #Adocia #BioChaperone #DrugDelivery #Peptides #Proteins #DDFSummit

📊 Adocia anounces its First Quarter 2026 financial results and provides a business update. 👉 Read more in the complete press release: https://lnkd.in/eUDKpkHt